

Adjuvants

Immunotherapy & Vaccine Development
From Avanti Research™

The Life Science business of Merck operates as MilliporeSigma in the U.S. and Canada.



* Merck is the exclusive supplier of Avanti Research™ to customers outside the United States and Canada.



Monophosphoryl Lipid A (MPLA) Adjuvants

MPLA 3D-PHAD™

The highly pure MPLA analog, 3D-PHAD™, provides a homogeneous synthetic equivalent for the deacylated MPLA derived from bacterial LPS. While comparable to bacterial MPLA and other synthetic MPLA analogs at eliciting an immune response in a liposomal adjuvant system, 3D-PHAD™ is less pyrogenic than its bacterial-derived mimic. Extensive preclinical testing with 3D-PHAD™ demonstrated equivalency to PHAD™, and human trials have been scheduled for launch. 3D-PHAD™ is protected under Pat No. 9,241,988. Licensing opportunities are available for vaccine or immunotherapy commercialization.





MPLA PHAD™

PHAD™ is a synthetic structural analog of monophosphoryl Lipid A (MPLA) that has been shown to boost the immune system through activation of the toll-like receptor 4 (TLR4) resulting in production of proinflammatory cytokines and antigen-specific effector CD4+ and memory CD8+ T cells. Also referred to as GLA, this adjuvant has been administered to well over 1000 human subjects without serious adverse events. PHAD™ is available in bulk quantities for vaccine development and commercial manufacturing.

MPLA 3D(6-acyl)-PHAD™

The MPLA structural analog, 3D(6-acyl)-PHAD™, is the synthetic MPLA most closely related to the reported structure of MPL® Adjuvant used in GSK's Adjuvant Systems AS01, AS02, and AS04. As with other synthetic MPLA analogs manufactured by Avanti™, it is structurally homogeneous and highly purified, and mimics the TLR4 agonist activity of bacterial MPLA.




MPLA PHAD™-504

PHAD™-504 was designed as a synthetic structural analog of detoxified MPLA derived from *E. coli* lipopolysaccharide (LPS). It is structurally similar to PHAD™, differing only in the length of a single fatty acid chain. As expected, the activity of PHAD™-504 is quite similar to that of PHAD™, making the two products interchangeable as adjuvants in vaccine or immunotherapy formulations.

Equivalence of Synthetic MPLAs


PHAD™, 3D-PHAD™, and 3D(6A)-PHAD™ have been tested extensively on animals using a variety of antigens. In all cases, these adjuvants exhibit a similar activity and safety profile to bacterially-derived MPL. The graph demonstrates the equivalency of the three synthetic adjuvants to the bacterially-derived MPL, when presented in a liposomal carrier system (DMPC/ DMPG/cholesterol).



TB Vaccines

Trehalose Dibehenate (TDB) and DDA

Incorporation of the glycolipid trehalose 6,6'-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound dimethyldioctadecylammonium (DDA) produce an adjuvant system which induces a powerful cell-mediated immune response and a strong antibody response, desirable for a high number of disease targets.



References

1. Larrouy-Maumus G, Layre E, Clark S, Prandi J, Rayner E, Lepore M, de Libero G, Williams A, Puzo G, Gilleron M. Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis. *Vaccine*. 2017 Feb 9. pii: S0264-410X(17)30159-7.
2. Derrick SC, Yabe I, Morris S, Cowley S. Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice. *Clin Vaccine Immunol*. 2016 Jul 5;23(7):638-47.
3. Rose F, Wern JE, Ingvarsson PT, van de Weert M, Andersen P, Follmann F, Foged C. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. *J Control Release*. 2015 Jul 28;210:48-57.

Cat. No.	Description
699855P	3D-(6-acyl) PHAD™ Monophosphoryl Hexa-acyl Lipid A, 3-Deacyl (Synthetic), powder
890810P	18:0 DDAB Dimethyldioctadecylammonium (Bromide Salt), powder
890810C	18:0 DDAB Dimethyldioctadecylammonium (Bromide Salt), chloroform
699500P	Kdo2-Lipid A (KLA) Di[3-deoxy-D-manno-octulosonyl]-lipid A (ammonium salt), powder
699851P	3A-MPLA Monophosphoryl Tri-acyl Lipid A (Synthetic), powder
699854P	4A-MPLA (isomer C3) Monophosphopdyl Tetra-acyl Lipid A, powder
699800P	MPLA (PHAD™) Monophosphoryl Lipid A (Synthetic) (PHAD®), powder
699852P	3D-PHAD™ Monophosphoryl 3-Deacyl Lipid A (Synthetic) Pat No. 9,241,988, powder
699810P	PHAD™-504 Monophosphoryl Lipid A-504, powder
890808P	22:0 Trehalose D-(+)-trehalose 6,6'-dibehenate, powder
890809P	Trehalose monooleate D-(+)-trehalose 6-monooleate, powder

Discover the following at SigmaAldrich.com/Avanti

- Storage and handling of lipids
- Fatty acid distribution
- Phase transition temperatures
- Miscibility of phospholipid binary mixtures
- Ionization constants of phospholipids
- Critical micelle concentrations (CMCs)

Product Showcase

Browse SigmaAldrich.com/Avanti to explore more than 2,400 Avanti Research™ products with 99% purity.

All products are manufactured by Avanti Research™ - A Croda Brand, and backed by the same high quality standards and informed techniques.

Because they're available from us, ordering is easy, inventory is reliable, and support is always within reach.

- Phospholipids
- Natural & Synthetic Lipids
- Sphingolipids
- Sterols
- Fluorescent Lipids
- Detergents
- Lipidomics
- Bioactive Lipids
- Fatty Acid Modified Lipids
- Headgroup Modified Lipids
- Coenzyme A and Derivatives
- Stable Isotopes and ESR Probes
- Polymers & Polymerizable Lipids
- Cationic Lipids (Transfection)
- Neutral Lipids
- Mini-Extruder

Merck KGaA
Frankfurter Strasse 250
64293 Darmstadt, Germany

© 2025 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

MK_FL6404EN 61030 01/2025